Entropy Technologies LP Makes New $4.68 Million Investment in Humana Inc. (NYSE:HUM)

Entropy Technologies LP purchased a new position in Humana Inc. (NYSE:HUM) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,767 shares of the insurance provider’s stock, valued at approximately $4,677,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pzena Investment Management LLC boosted its position in shares of Humana by 538.7% during the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock valued at $866,250,000 after acquiring an additional 1,955,375 shares during the last quarter. Davis Selected Advisers boosted its position in shares of Humana by 16.1% during the 2nd quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider’s stock valued at $863,640,000 after acquiring an additional 321,233 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Humana by 118.9% during the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after acquiring an additional 774,085 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Humana by 2.1% during the 2nd quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock valued at $442,396,000 after acquiring an additional 24,842 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board boosted its position in shares of Humana by 11,647.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after acquiring an additional 1,050,459 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

HUM opened at $282.44 on Tuesday. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18. The business’s fifty day simple moving average is $289.38 and its 200-day simple moving average is $332.82. The company has a market capitalization of $34.01 billion, a price-to-earnings ratio of 25.52, a PEG ratio of 2.28 and a beta of 0.52. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. On average, equities research analysts anticipate that Humana Inc. will post 15.83 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is currently 31.36%.

Analyst Ratings Changes

HUM has been the subject of a number of research reports. UBS Group lowered their target price on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, October 4th. Royal Bank of Canada decreased their price target on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. TD Cowen increased their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Leerink Partnrs lowered Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Wells Fargo & Company decreased their price target on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.